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Appropriate patterns of DNA methylation and histone modifications are required to assure cell identity, and
their deregulation can contribute to human diseases, such as cancer. Our aim here is to provide an overview
of how epigenetic factors, including genomic DNA methylation, histone modifications, and microRNA regu-
lation, contribute to normal development, paying special attention to their role in regulating tissue-specific
genes. In addition, we summarize how these epigenetic patterns go awry during human cancer development.
The possibility of ‘‘resetting’’ the abnormal cancer epigenome by applying pharmacological or genetic strat-
egies is also discussed.Introduction
Normal development appears to take place through a unidirec-
tional process characterized by a step-wise decrease in devel-
opmental potential and an activation of specific gene programs
that trigger differentiation into specialized cell types. Once
established, temporal and spatial activation and silencing of
specific genes in a cell-type-specific pattern must be stable
over many cell generations and long after inductive develop-
mental signals have disappeared. Equally important, a cell
must silence expression of genes specific to other cell types to
secure its fate. Repression must be maintained throughout the
life of the individual in normal development, and epigenetic
mechanisms, which are defined as heritable changes in gene
function that do not alter the primary DNA sequence, are ideal
for regulating such events. The best-studied epigenetic modifi-
cation is DNA methylation, which consists of the addition of
amethyl group to carbon 5 of the cytosinewithin the dinucleotide
CpG. It has been estimated that 3%–6% of cytosines are
methylated in normal tissues and that this DNA methylation is
necessary for controlling gene expression of tissue-specific,
housekeeping or imprinted genes and also for maintaining
genomic stability through silencing transposable elements of
the genome (Esteller, 2007).
DNA methylation does not work alone and occurs in the
context of other epigenetic modifications, such as histone
modifications. Histone tails may undergo many posttranslational
chemical modifications, including acetylation, methylation,
phosphorylation, ubiquitylation, and sumoylation. For instance,
the different statuses of acetylation and methylation of specific
lysine residues are considered crucial histone marks affecting
chromatin structure and gene expression (Kouzarides, 2007).
Additionally, recent advances in the rapidly evolving field of
epigenetics have demonstrated the extensive role of noncoding
RNAs, especially miRNA expression, in maintaining global
expression patterns during normal development (Sharma et al.,
2010). Although several small-scale studies of specific epige-
netic marks have provided limited information about the regula-
tion of genes from different pathways, there is a need for knowl-698 Developmental Cell 19, November 16, 2010 ª2010 Elsevier Inc.edge in a broader perspective. A range of matters remains to be
resolved, such as the relationships between the epigenetic
players (the ‘‘epigenetic code’’) and how the environment and/
or aging modulate the epigenetic marks. Some of this could be
achieved by analyzing patterns on a genome-wide scale, an
approach that has at last become possible thanks to recent tech-
nological advances (Bernstein et al., 2007; Barski et al., 2007;
Irizarry et al., 2009).
It is clear that a comprehensive knowledge of the human
epigenome will allow a fuller understanding of normal develop-
ment, aging, abnormal gene control in cancer, and other
diseases, as well as the role of the environment in human health.
This is the main goal of the International Human Epigenome
Consortium (IHEC) and the Roadmap Epigenomics Program at
NIH Fund (http://nihroadmap.nih.gov/epigenomics); however,
we must bear in mind that there is no single epigenome but,
rather, many different ones that are characteristic of normal
and diverse pathological states. It is clear that the information
extracted from the whole-genome assays will help us under-
stand the role of epigenetic marks in normal development and
in diseases such as cancer. The aim of the present review is
to provide an overview of how epigenetic factors, including
genomic DNA methylation, histone modifications, and micro-
RNA regulation, contribute to normal development, paying
special attention to their role in the establishment of cell identity.
In the second part, we will focus on how tissue-specific epige-
netic patterns go awry during human cancer development.
Epigenetic Changes during Normal Development
It is well described that DNA methylation patterns undergo
genome-wide alterations that occur immediately after fertiliza-
tion and during early preimplantation development (Mayer
et al., 2000; Reik et al., 2001) and that enrichment of indi-
vidual histone modifications (such as H3K9me, H3K4me and
H3K27me3) also varies in a specific manner at different stages
of development (Reik, 2007). Apart from the extensive chromatin
remodeling that occurs during early differentiation, epigenetic
factors must guarantee the activation and maintenance of
Figure 1. Gene-Specific Changes of the
Epigenetic Landscape during Mammalian
Development
CpG promoter hypermethylation and histone
marks regulate the expression levels of genes
that relate to pluripotency, that are required for
tissue identity, and that occur in alternative line-
ages in the transition from a zygote to a highly
specialized adult cell. In germ cells and the zygote,
key developmental and lineage genes are main-
tained in a transcriptionally ‘‘poised’’ but inactive
state, e.g., by bivalent histone marks. During
differentiation, lineage-specific genes must be
activated by active epigenetic marks, while
those genes required for alternative lineages
and pluripotency genes must be permanently
silenced. H3K27me3, trimethylated histone H3
at lysine 27; H3K4me3, trimethylated histone H3
at lysine 4; H3K9me3, trimethylated histone H3 at
lysine 9, H3K9Ac, acetylated histone H3 at lysine 9.
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the expression of pluripotency-related genesmust be abolished,
while housekeeping genes and appropriate patterns of tissue-
specific genes must be guaranteed (Figure 1). In the following
sections, we will discuss how DNA methylation, histone modifi-
cations, and microRNA regulation could assure cell-type speci-
ficity in normal development.
Roles for DNA Methylation in Differentiation, Genomic
Stability, X-Inactivation, and Imprinting
Gene expression and DNA methylation are inversely correlated
inmany genes thatmust be developmentally controlled following
cell-type specification in early development. For example, the
pluripotency genesOct4 andNanog are expressed in preimplan-
tation embryos and in the germline, and their promoters are
hypermethylated and silenced in differentiated cells (Hattori
et al., 2004; Hattori et al., 2007). But not only pluripotency-
related genes are hypermethylated during differentiation.
A number of genes are unmethylated in germline cells but
methylated in somatic cell types, such as theMAGE (melanoma
antigen-encoding genes) family (De Smet et al., 1999). Genome-
wide studies characterizing the de novo hypermethylation of
promoters during differentiation in mouse models identified 5%
of the CpG islands as hypermethylated and, in consequence,
silenced in somatic tissues, but not in germline cells (Mohn
et al., 2008; Song et al., 2005). A similar result was identified in
human tissues, where various methylation studies identify testis-
and sperm-specific hypomethylation with respect to several
somatic tissues (Schilling and Rehli, 2007; Shen et al., 2007).
DNA hypermethylation of repetitive genomic sequences has
also been proposed as a mechanism to prevent chromosomal
instability, translocations and gene disruption caused by the
activation of transposable DNA sequences or endoparasitic
sequences (Xu et al., 1999). In contrast to developmental
genes, mobile sequences of the genome need to be silenced
completely and stably to prevent them from moving around the
genome (Reik, 2007). According to this idea, many transposon
families are both methylated and marked by repressive histone
modifications, for example H3K9me3. Furthermore, some trans-Dposon families, such as the intracisternal A particles, are even
resistant to the erasure of DNA methylation in the zygote,
possibly resulting in epigenetic inheritance across generations
(Reik, 2007).
In addition, DNA methylation is implicated in establishing
patterns of monoallelic gene expression (Figure 1). For example,
X chromosome inactivation (Xi) involves monoallelic repression
of genes (i.e., on one of the two X chromosomes) in female cells
to equalize the imbalance of the ‘‘extra’’ X chromosome gene
expression as compared to the one X chromosome in males.
Random Xi is initiated in the epiblast (Allegrucci et al., 2005),
and the inner cell mass (ICM) cells reactivate Xi in the late
blastocyst, while extraembryonic cells (trophoectoderm and
primitive endoderm) maintain Xi (Kiefer, 2007). Many epigenetic
mechanisms promote heterochromatization of Xi. First, the
X-inactivated chromosome acquires both K3H9me3 and
H3K27me3 but lose histone acetylation and the activating
mark H3K4me3 (Plath et al., 2003; Valley et al., 2006). Second,
there is a substitution of the core histone H2A with the histone
variant MacroH2A (Chadwick and Willard, 2003). Third, there is
a hypermethylation of CpG islands (Reik and Lewis, 2005). All
of these epigenetic marks guarantee the stability of the Xi for
the lifetime of the individual.
Furthermore, genomic imprinting must be included as
a second example of monoallelic expression in which epigenetic
chromosomal modifications drive differential gene expression
according to which parent transmitted the chromosome to the
progeny. Expression is exclusively due either to the allele
inherited from the mother (e.g., the H19 and CDKN1C genes)
or to that inherited from the father (e.g., IGF2). This inheritance
process is independent of the classical Mendelian model. DNA
methylation has been widely described as the main mechanism
for controlling genes subjected to imprinting (Kacem and Feil,
2009). One model of this regulation is based on the cluster orga-
nization of imprinted genes. The structure within clusters allows
them to share common regulatory elements, such as noncoding
RNAs and DMRs (Differentially Methylated Regions). DNA meth-
ylation of DMRs is thought to interact with histone modificationsevelopmental Cell 19, November 16, 2010 ª2010 Elsevier Inc. 699
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expression of imprinted genes; for instance, H3K27me3 and
H3K9me2 together with CpG promoter hypermethylation are
involved in silencing imprinted genes (Henckel et al., 2009).
Furthermore, the aforementioned regulatory elements usually
control the imprinting of more than one gene, giving rise to
imprinting control regions (ICRs). This cluster organization,
observed in 80% of imprinted genes and the specific DNAmeth-
ylation patterns associated with DMRs are two of the main
characteristics of imprinted genes. These genes have diverse
roles in growth and cellular proliferation, and specific patterns
of genomic imprinting are established in somatic and germline
cells (Dolinoy et al., 2007; Feil and Berger, 2007). Deletions or
aberrations in DNAmethylation of ICRs lead to loss of imprinting
and inappropriate gene expression (Murrell et al., 2008), and they
are usually associated with several syndromes and pathologies
such as cancer.
Tissue-Specific DNA Methylation in Somatic Cells
It has long been speculated that cytosine methylation is involved
in the establishment and maintenance of cell-type-specific
expression of developmentally regulated genes; however, there
are no clear examples of such genes, especially in humans.
A small but significant proportion of genes have been identified
as being differentially methylated between normal tissues and
cell types (Imamura et al., 2001; Futscher et al., 2002; Rauch
et al., 2009). Expression of the human MASPIN (SERPINB5)
gene, an autosomal gene, is limited to certain types of epithelial
cells, but no detectable amounts of the gene are found in skin
fibroblasts, lymphocytes, bone marrow, heart, or kidney. The
cytosine methylation status of SERPINB5 shows an inverse
correlation with SERPINB5 expression in normal cells (Futscher
et al., 2002). Consistent with this finding, other genes, such as
rSPHK1 and hSLC6A8, showpromoter hypermethylation associ-
ated with gene silencing in specific tissues (Grunau et al., 2000;
Imamura et al., 2001). For example, the rSPHK1 promoter region
is hypomethylated in the adult brain, whereSphk1a is expressed,
whereas it is hypermethylated in theadult heart,where thegene is
not expressed (Imamura et al., 2001). Using an array representing
over 17,000 CpG islands, Illingworth et al. (2008) established
that 6%–8% of CpG islands are methylated in genomic DNA
from human blood, brain, muscle, and spleen. Interestingly,
some of these genes represent genetic loci that are essential
for development, including HOX and PAX transcription factor
family members (Illingworth et al., 2008; Rauch et al., 2009).
These results support the hypothesis posited more than 25
years ago that cell-type-specific patterns of cytosine methyla-
tion mediate control of cell-type-specific gene expression and,
by extension, cellular differentiation. However, profiling of CpG
methylation at chromosomes 6, 20, and 22 identifies several
CpG islands that are differentially methylated when eight
somatic tissues were compared (Eckhardt et al., 2006). Specifi-
cally, authors found that 17% of the analyzed genes (873) were
differentially methylated in their 50 UTRs, but only in about one-
third of the differentially methylated 50 UTRs could an inverse
correlation with transcription be established (Eckhardt et al.,
2006). Further work is needed to test whether this absence of
correlation is due to limitations of the analytical techniques or
to the existence of additional methylation-independent regula-
tory mechanisms.700 Developmental Cell 19, November 16, 2010 ª2010 Elsevier Inc.Cell Identity and Histone Modifications
The b-globin locus offers one of the best-studied examples of the
regulatory relationship between histone modifications and
developmental expression of genes, in part because vertebrates
express different globin genes at different stages of develop-
ment. Initial small-scale studies of the murine b-globin locus
revealed acetylated histones associated with globin gene
promoters in a tissue-specific and developmentally regulated
manner (Bulger et al., 2003). Furthermore, H3K4me2 generally
follows the acetylation process (Kiefer et al., 2008). We now
knowa considerable amount about the characterization of global
levels of histone modifications in differentiated mammalian
tissues, mainly thanks to the development of large-scale tech-
niques (ChIP-Seq, ChIP on chip, among others) (Barski et al.,
2007; Bernstein et al., 2007).
T cells, especially with respect to their methylation and acety-
lation marks, are one of the most widely employed biological
systems in the study of how histone modifications influence
cell fate. Differentiation of CD4+ T cells into their corresponding
subtypes appears to be controlled by various layers of modifica-
tions. First, the cytokine genes that define lineage identity (IFN-g,
IL-4, and IL-17 for Th1, Th2, and Th17 cells, respectively) are
enriched in the activation mark H3K4me3 in the correct lineage
(Schoenborn et al., 2007; Akimzhanov et al., 2007). It is important
to note that the repressive mark H3K27me3 does not correlate
with the genes that are not expressed in the appropriate lineage
(Wei et al., 2009), indicating that some additional repressive
marks could be involved or that some degree of cellular plasticity
may persist. A similar scenario was found for the transcription
regulators of lineage specificity, including Foxp3, RORgt,
T-bet, and GATA-3 (Wei et al., 2009; Cuddapah et al., 2010).
In addition, genome-wide studies have indicated that the
genomes of differentiated T cells (Roh et al., 2006; Barski
et al., 2007) also possess bivalent domains, marked with both
H3K27me3 and H3K4me3, similar to those described for embry-
onic stem cells (ESCs) (Bernstein et al., 2006; Azuara et al.,
2006). Similarly, the bivalent domains were also described in
genome-wide approaches for the study of histone modifications
during differentiation of multipotent human primary hematopoi-
etic stem cells/progenitor cells into erythrocyte precursors
(Cui et al., 2009) or in the acquisition of oligodendrocyte identity
(Liu and Casaccia, 2010). As a conclusion to these reports, it
seems that certain histone modifications can preserve a poised
but inactive gene state in embryonic stem cells (Bernstein et al.,
2006, Barski et al., 2007) in more lineage-restricted but nonethe-
less multipotent progenitors (Cui et al., 2009; Orford et al., 2008)
and in terminally differentiated cells that can be reprogrammed in
the presence of external stimuli (Roh et al., 2006).
Epigenetic Control of MicroRNAs in Normal
Development
MicroRNAS (miRNAs) are small, approximately 22 nucleotide-
long, non-coding RNAs that function as endogenous posttran-
scriptional silencers of target genes (Ambros, 2004). miRNAs
are expressed in a tissue-dependent manner and are important
regulators of several cellular processes, including proliferation,
differentiation, apoptosis, and development (He and Hannon,
2004). The list of miRNAs identified in the human genome and
their corresponding target genes is rapidly lengthening, vali-
dating their role in the maintenance of global gene expression
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regulation of miRNA and lineage commitment has recently
been established (Nomura et al., 2008; Szulwach et al., 2010).
First, the coding transcript of the brain-specific miR-184,
imprinted and exclusively expressed from the paternal allele,
may be induced by methyl-binding protein MeCP2 release
(Nomura et al., 2008). Likewise, mir-137, an intrinsic modulator
of adult neurogenesis (Silber et al., 2008), is also subjected to
epigenetic control mediated by MeCP2 (Szulwach et al., 2010).
Sox2, a gene with key functions in stem cell self-renewal (Ferri
et al., 2004), acts directly in tandem with MeCP2 for proper tran-
scriptional regulation of mir-137 in adult neurogenesis (Szulwach
et al., 2010). To understand the pathways by which mir-137
modulates adult neurogenesis, the authors looked for putative
gene targets of mir-137 regulation. Interestingly, they found
that one of miR-137 targets is EzH2, a H3K27 methyltransferase
and component of the Polycomb protein complexes. In conse-
quence, mir-137 mediated repression of EzH2 is associated
with a global decrease in H3K27me3.
Epigenetic Changes in Cancer Cells
Initially, cancer was thought to be solely a consequence of
genetic changes in key tumor-suppressor genes and oncogenes
that regulate cell proliferation, DNA repair, cell differentiation,
and other homeostatic functions. However, the study of epige-
netic mechanisms in cancer during the last decade, such as
DNAmethylation, histone modification, nucleosome positioning,
and micro-RNA expression, has provided extensive information
about the mechanisms that contribute to the neoplastic pheno-
type through the regulation of expression of genes critical to
transformation pathways. Cancer cells have a specific epige-
nome. Regarding DNAmethylation, the low level of CpGmethyl-
ation in tumors compared with that in their normal-tissue
counterparts was one of the first epigenetic alterations to be
found in human cancer (Feinberg and Vogelstein, 1983; Goelz
et al., 1985). From a functional point of view, hypomethylation
in cancer cells is associated with a number of adverse outcomes,
including chromosome instability, activation of transposable
elements, and loss of genomic imprinting. Decreased methyla-
tion of repetitive sequences in the satellite DNA of the pericentric
region of chromosomes is associated with increased chromo-
somal rearrangements, mitotic recombination, and aneuploidy
(Eden et al., 2003; Karpf and Matsui, 2005). Intragenomic endo-
parasitic DNA, such as L1 (long interspersed nuclear elements)
(Schulz, 2006) and Alu (recombinogenic sequence) repeats, are
silenced in somatic cells and become reactivated in human
cancer. Furthermore, the effect on the loss of imprinting must
also be considered. Wilms’ tumor, a nephroblastoma that typi-
cally occurs in children, is the best-characterized imprinting
defect associated with increased susceptibility to cancer
(Bjornsson et al., 2007). At a specific level, aberrations in DNA
methylation patterns of the CpG islands in the promoter regions
of tumor-suppressor genes are accepted as being a common
feature of human cancer (Esteller, 2008). CpG island promoter
hypermethylation affects genes from a wide range of cellular
pathways, such as cell cycle, DNA repair, toxic catabolism, cell
adherence, apoptosis, and angiogenesis, among others (Estel-
ler, 2008), and may occur at various stages in the development
of cancer.DAlthough the ultimate causes of aberrant DNA methylation
remain to be determined, several studies showed that alterations
in the DNAmethylome could be directly affected by diet, xenobi-
otic chemicals, and exogenous stimuli, such as inflammation or
viral/bacterial infection. Diets that are deficient in folate and
methionine, which are necessary for normal biosynthesis of
S-adenosylmethionine (SAM), the methyl donor for methylcyto-
sine, lead to DNA hypomethylation and aberrant imprinting of
insulin-like growth factor 2 (IGF2) (Waterland et al., 2006).
Furthermore, particular genetic variants in the enzymes involved
in the metabolism of folate and methionine are associated with
different DNA methylation levels (Paz et al., 2002). Exposure to
metals, such as arsenic (Benbrahim-Tallaa et al., 2005),
cadmium (Poirier and Vlasova, 2002), lead (Silbergeld et al.,
2000), nickel (Salnikow and Costa, (2000)), and chromium (Wei
et al., 2004), is linked to changes in the expression of epigenet-
ically controlled genes via interactions with DNA-methylation-
associated enzymes, histone acetyltransferase, and histone
deacetylase enzymes. Between exogenous stimuli, it has been
described that altered patterns of DNA methylation could be
associated with Helicobacter pylori infection of gastric epithelial
cells and contribute to gastric cancer risk (Niwa et al., 2010). In
addition, chronic inflammation has been proposed as possible
inducer of aberrant methylation in liver cancers or ulcerative
colitis-associated colon cancers (Kondo et al., 2000; Issa et al.,
2001). However, a causal role of most of these inductors in
DNA methylation patterns remains to be established. In this
regard, studies performed with genetically identical individuals,
such as mice clones (Rideout et al., 2001) and human monozy-
gotic twins (Fraga et al., 2005a), could be an excellent method
for understanding the environment-epigenome interaction.
Because of the complexity of permutations and combinations,
less is known about the patterns of histone modification disrup-
tion in human tumors. Results have shown that the CpG
promoter hypermethylation event in tumor-suppressor genes in
cancer cells is associated with a particular combination of
histone markers and the opposite of that observed in normal
cells: deacetylation of histones H3 and H4, loss of H3K4 trime-
thylation, and gain of H3K9 methylation and H3K27 trimethyla-
tion (Jones and Baylin, 2007). The association between DNA
methylation and histone modification aberrations in cancer
also occurs at the global level. In human and mouse tumors,
histone H4 loses monoacetylated and trimethylated lysines 16
and 20, respectively, especially in repetitive DNA sequences
(Fraga et al., 2005b). Furthermore, histone acetylation and dime-
thylation of five residues in histones H3 and H4 also define two
disease subtypes with distinct risks of tumor recurrence in
patients with low-grade prostate cancer (Seligson et al., 2005).
Finally, as DNA methylation and histone modifications act as
mechanisms for controlling cellular differentiation, allowing the
expression only of tissue-specific and housekeeping genes in
somatic differentiated cells, it is possible that the inappropriate
(re)activation of tissue-specific genes also plays a role in cancer
(Fan et al., 2008). The epigenetic alterations affecting genes
expressed in a tissue-specific manner and their involvement in
tumor development are briefly reviewed below.
Tumor-Type-Specific CpG Island Hypermethylation
Aberrations in DNA methylation patterns of the CpG islands in
the promoter regions of tumor suppressor genes are acceptedevelopmental Cell 19, November 16, 2010 ª2010 Elsevier Inc. 701
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Figure 2. Distribution of CpG Islands in Promoters of Housekeeping and Tissue-Specific Genes
Promoters associated with CpG islands are found in all known housekeeping genes and half of all tissue-specific genes. Generally, housekeeping genes are
unmethylated in normal cells, while tissue-specific genes may be unmethylated or methylated, depending on their requirement for lineage commitment. In
a cancer cell, some of the housekeeping genes become aberrantly hypermethylated. Gains and losses of CpG hypermethylation can be observed for tissue-
specific genes that are aberrantly expressed in cancer. CpG-poor regions are always found in tissue-specific genes, where expression is independent of
CpG methylation status. Some examples of genes relevant to each of these circumstances are illustrated.
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discovery of silencing was performed in the promoter of the reti-
noblastoma (Rb) tumor suppressor gene (Greger et al., 1989;
Sakai et al., 1991), but hypermethylation of genes like VHL (asso-
ciated with von Hippel-Lindau disease), p16INK4a, hMLH1
(a homolog of Escherichia coliMutL), andBRCA1 (breast-cancer
susceptibility gene 1) were subsequently described (Herman and
Baylin, 2003). It is expected that improvements in genome-wide
epigenomic studies will increase the number of hypermethylated
tumor suppressor genes in a broad spectrum of tumors; by 2001,
100–400 instances of gene-specific methylation had already
been noted in particular tumors (Esteller et al., 2001a).
A CpG island hypermethylation profile of human primary
tumors has emerged, which shows that the CpG island hyper-
methylation profiles of tumor-suppressor genes are specific to
the cancer type (Costello et al., 2000; Esteller et al., 2001a).
Each tumor type can be assigned a specific, defining DNA
‘‘hypermethylome,’’ rather like a physiological or cytogenetic
marker. These marks of epigenetic inactivation occur not only
in sporadic tumors but also in inherited cancer syndromes, in
which hypermethylation may be the second lesion in Knudson’s
two-hit model of cancer development (Esteller et al., 2001b).
Although initial results have been obtained in cancer cell lines
(Paz et al., 2003; Ehrich et al., 2008), CpG hypermethylation
‘‘maps’’ have been identified for primary tumors, including acute702 Developmental Cell 19, November 16, 2010 ª2010 Elsevier Inc.myeloid leukemia (Figueroa et al., 2010), glioblastomas (Martinez
et al., 2009), astrocytomas (Wu et al., 2010a), and ovarian epithe-
lial carcinoma (Houshdaran et al., 2010), among others.
Aberrant Promoter Hypermethylation of Housekeeping
Genes in Cancer
In contrast to tissue-specific genes that are expressed at a much
higher level in a single tissue type than in others, some genes are
constitutively expressed in all tissues. These genes have been
referred to as housekeeping genes and include a wide spectrum
of genes essential for cell metabolism, such as cell-cycle, ribo-
somal RNA, or stress defense-related genes. The regulatory
mechanisms underlying the differential expression patterns of
housekeeping genes compared with tissue-specific genes are
also poorly characterized. For a long time, it was accepted that
all known housekeeping genes and half of the tissue-specific
genes have associated CpG islands (Figure 2) (Antequera,
2003). In agreement with this, a recent report systematically
and quantitatively demonstrated the enrichment of CpG islands
in housekeeping genes, although the pattern tends to be more
variable for tissue-specific genes (with a prevailing depletion of
CpG islands) (She et al., 2009). Normally, housekeeping genes
have a nonmethylated CpG island tightly associated with their
promoter (Caiafa and Zampieri, 2005). Because such genes
tend to be expressed ubiquitously and because these autosomal
CpG islands are by and large poorly methylated, housekeeping
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seems that this is an oversimplification and several genes that
are considered as constitutively expressed in all cells are
known to be inactivated by CpG promoter hypermethylation in
cancer cells, affecting a wide range of cellular pathways, such
as cell cycle (Rb, p16INK4a, p15INK4b), DNA repair (BRCA1,
MGMT, MLH1, WRN), transcription factors (BMAL1, GATA-4,
GATA-5, ID4, VHL), epigenetic enzymes (NSD1, RIZ1), receptors
(AR, CRBP1, ESR1, PR, TSHR), signal transduction (APC,
RASSF1A, LKB1, SFRP, TLE1, WIF1), toxic catabolism and
drug resistance (GSTP1), metastasis and cell invasion (CDH1,
CDH13, FAT, TIMP3), apoptosis (DAPK, TMS1, CASP8), and
angiogenesis (THBS1), among others (reviewed in Costello and
Plass, 2001; Esteller, 2007; Jones and Baylin, 2007; Esteller,
2008). Interestingly, it has been proposed that CpG hypermethy-
lation events in cancer were significantly more likely to occur in
the promoters of those genes with enriched Polycomb occu-
pancy and the presence of bivalent histone domains (3mK4H3 +
3mK27H3) in embryonic stem cells (Schlesinger et al., 2007;
Ohm et al., 2007; Widschwendter et al., 2007).
Increased CpG Methylation in Tissue-Specific Genes
during Tumorigenesis
We have described how CpG methylation also constitutes
a mechanism of epigenetic control of differentiation genes,
allowing the expression in a time- and tissue-dependent manner.
These same genes can also be deregulated in cancer by aber-
rant CpG promoter hypermethylation. For example, the tissue-
specific expression of maspin, which encodes the mammary
serine protease inhibitor protein and is expressed only in cells
of epithelial origin, is epigenetically regulated by DNA methyla-
tion (Futscher et al., 2002). Additionally, the aberrant CpG hyper-
methylation of maspin leads to gene silencing in cancers, such
as breast, thyroid, skin, and colon (Boltze et al., 2003; Bettstetter
et al., 2005; Khalkhali-Ellis, 2006; Wu et al., 2010b). A second
example is that of the MCJ (methylation-controlled DNAJ)
gene, which showed restricted expression associated with
high levels of methylation in epithelial cells, but not in lymphoid
and mesenchymal-derived cells (Strathdee et al., 2004). The
methylation of the MCJ CpG island is associated with chemo-
therapy resistance in ovarian cancer (Strathdee et al., 2004),
and aberrant epigenetic inactivation of MCJ may play a role in
the development of a range of pediatric brain tumor types
(Lindsey et al., 2006). The homeobox gene HOXA5 is another
example of a tissue-specific gene in which CpG methylation
plays a dual role in establishing patterns of expression in normal
tissues and contributing to human malignancies. Hypermethyla-
tion of HOXA5 could be detected in adult hematopoietic cells,
but not in epithelial cells and, additionally, in acute myeloid
leukemia (Strathdee et al., 2007).
Loss of CpG Methylation in Tissue-Specific Genes
during Tumorigenesis
DNA hypomethylation in tumors has been associated with the
activation of expression of a discrete number of genes (Baylin
et al., 1998). The major contribution of DNA hypomethylation to
tumor development is its association with genomic instability,
through the deregulation of transposable elements, pericentro-
meric regions, or activation of endoparasitic sequences.
However, the range of affected loci also includes growth regula-
tory genes, imprinted genes, developmentally critical genes, andDtissue-specific genes. Of the latter, the best characterized are
the germ-cell-specific tumor antigen genes such as the MAGE,
BAGE, LAGE, and GAGE gene families. Repression of these
germline-specific genes (CG genes) in normal somatic tissues
is because of DNA methylation (De Smet et al., 1999), but these
CG genes are expressed in histologically distinct types of malig-
nant human tumors and transcriptional activation is correlated
with hypomethylation (Weber et al., 2007; Almeida et al., 2009).
The main consequence of the activation of CG genes in cancer
is the production of tumor-specific antigens leading to immune
rejection. Examples of CG genes hypomethylated in cancer are
widely reported in the literature, including theMAGE gene family
in testicular and hepatocellular cancer (De Smet et al., 2004; Qiu
et al., 2006) and the BAGE loci in breast, ovarian, and myeloma
cancer (Grunau et al., 2005).
Although other genes—such as synuclein gamma (associated
with metastasis; Gupta et al., 2003), S100P, and claudin-4 (Sato
et al., 2004)—are known to be hypomethylated in cancers, the
correlation between promoter hypermethylation and gene
repression seems less straightforward in these cases (Dokun
et al., 2008).
Deregulation of miRNAs in Cancer Cells
The deregulation of miRNA expression has also been linked
to human developmental defects and to tumor progression.
miRNAs can function as tumor suppressors or oncogenes,
depending upon their target genes. Changes in miRNA expres-
sion can be achieved through various mechanisms, including
chromosomal abnormalities, transcription factor binding, and
genetic alterations (Deng et al., 2008). For example, miRNA
expression and activity can be influenced by impairment of
miRNA processing machinery, such as the recently identified
mutations of TRBP2 (an essential functional partner of the
DICER1 complex) in sporadic and hereditary carcinomas with
microsatellite instability (Melo et al., 2009).
In addition, the expression of miRNAs may be affected by
epigenetic changes, such as the methylation of CpG islands
and accompanying changes in histone modifications. The initial
report by Saito et al. (2006) demonstrated that mir-127, which
has tumor-suppressor properties, was suppressed by promoter
hypermethylation in cancer cells from different tissue types.
Furthermore, this epigenetic repression of mir-127 was associ-
ated with changes in histone modifications and may be reversed
by adding chromatin-modifying drugs (Saito et al., 2006) in T24
bladder cancer cells. Subsequently, using DNA methyltransfer-
ase DNMT1 and 3b mutant cells, mir-124a was identified as an
epigenetically regulated modulator of the expression of the
CDK6 tumor-suppressor, which phosphorylates Rb. mir-124a
CpG hypermethylation recruits MeCp2 and MBD2 transcrip-
tional repressors and is associated with a reduction in active
histone marks, such as acetylation of histones H3 and H4 and
trimethylation of histone H3 (lysine 4) in human cancer cells.
DNA demethylation drugs could revert this phenotype (Lujambio
et al., 2007). Indeed, several groups have now used strategies
based on the treatment of cancer cell lineswithDNA-demethylat-
ing reagents and/or histone deacetylase inhibitors in vitro to
study changes inmiRNAexpression (Lujambio et al., 2008;Grady
et al., 2008; Kozaki et al., 2008; Furuta et al., 2010). These works
enabled awide range of tumor-suppressormiRNAswith aberrant
hypermethylation to be identified in several types of cancer,evelopmental Cell 19, November 16, 2010 ª2010 Elsevier Inc. 703
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Reviewsuch as mir-9-1 (Lehmann et al., 2008), mir-193a (Kozaki
et al., 2008), mir-137 (Kozaki et al., 2008), mir-342 (Grady et al.,
2008), mir-203 (Bueno et al., 2008), mir-34b/c (Toyota et al.,
2008), and mir-1 (Datta et al., 2008). These miRNAs are, in turn,
associated with the deregulation of key genes such as CDK6,
TGIF2 (Lujambio et al., 2008), or centralmediators ofp53 function
(Bommer et al., 2007). Likewise, the SOX4 oncogene is the
target of mir-129-2 and is overexpressed in endometrial cancer
when mir-129-2 is aberrantly hypermethylated (Huang et al.,
2009). These findings suggest that the profile of miRNAmethyla-
tion could be a useful tool in cancer diagnosis and prognosis.
Interestingly, as seen during normal development (q.v. mir-137
and EzH2 discussed above), cancers can also use miRNAs
reciprocally to target the epigenetic machinery. For example, in
prostate and bladder tumors (Varambally et al., 2008), EzH2 is
regulated by mir-101 instead of mir-137. Prostate cancer cells
(Noonan et al., 2009) control HDAC1 via mir-449a. And mir-29b
directly represses expression of DNMT3A and DNMT3B, result-
ing in DNA hypomethylation in acute myeloid leukemia (Garzon
et al., 2009). Re-expression of mir-143, which also controls
DNMT3A expression, reduces tumor cell proliferation in in vitro
colon cancer cells (Ng et al., 2009). All of these reports strongly
suggest important mechanisms of crosstalk between miRNAs,
DNA methylation, and histone modifications. Indeed, there is
increasing information about the specific epigenetic control of
miRNA clusters, defined as a set of miRNAs grouped by their
close proximity or sequence conservation (Tsai et al., 2009). A
comprehensive analysis showed that approximately 37% of all
known human miRNAs appear in clusters (Altuvia et al., 2005).
Expression of a large miRNA cluster located on human chromo-
some 19 (C19MC) was observed in normal placental tissue but
was repressed in cervical cancer cell lines and gastric cancer
cells. These differential patterns of expression correlate well
with the hypomethylated or hypermethylated status in normal
or cancer cells, respectively (Tsai et al., 2009).
Tissue-Specific Aberrations of Histone
Modifications in Cancer
Although alterations in the levels of DNA methylation are
commonly observed in cancer, no clear genetic lesions have
been described in the DNA-methylation machinery in cancer
cells. However, histone-modifier genes have tissue-type-
specific patterns of expression in cancer, which could explain
the differences in specific histone modifications between tumor
types (Ozdag et al., 2006). Interestingly, genetic alterations of
histone modifiers enzymes are detected in a tissue-specific
manner, and the landscape varies if solid tumors or hematolog-
ical malignancies are compared (Table 1).
For instance, inappropriate silencing of the Nuclear receptor
SET domain protein 1 (NSD1) gene by CpG hypermethylation
of its promoter results in decreases of H3K36me3 and
H4K20me3; this phenomenon plays an important role in the
Sotos overgrowth syndrome and in tumors of the nervous
system (neuroblastomas and gliomas) but is conspicuously
absent from leukemia, lymphoma, and colon or breast cancers
(Berdasco et al., 2009). CpG island hypermethylation has been
also described for the histone methyltransferase RIZ1 in several
types of human cancer (Du et al., 2001). For more information on
the wide variety of genetic alterations in histone modifiers that
have now been observed, see Table 1.704 Developmental Cell 19, November 16, 2010 ª2010 Elsevier Inc.It is intriguing to note that solid tumors are more commonly
associated with point mutations, deletions, gene amplification,
and alterations in expression levels; however, occasional chro-
mosomal translocations are observed. One example is the zinc
finger gene SUZ12 (suppressor of zeste 12 homolog), which
has been identified at the breakpoints of a recurrent chromo-
somal translocation reported in endometrial stromal sarcoma
(Panagopoulos et al., 2008). The protein is a component of
the PRC2/EED/EZH2 complex, which methylates H3K9 and
H3K27 and is also a recruiting platform for DNA methyltrans-
ferases, leading to the transcriptional repression of affected
target genes (such as HOXC8, HOXA9, MYT1, and CDKN2A).
Recombination of SUZ12 results in fusion with the zinc finger
domain protein JAZF1, affecting cell proliferation and survival
through a pathway that depends on H3K27me3 levels (Li et al.,
2007).
Such chromosomal translocations are much more common in
hematological malignancies than in solid tumors. The mixed-
lineage leukemia 1 (MLL1/ALL-1/HRX) histone methyltransfer-
ase is commonly found fused by translocation to one of more
than 50 known partners in aggressive myeloid and lymphoid
leukemias (Canaani et al., 2004). MLL1 regulates transcription
at least in part by means of H3K4 methylation, and it controls
the expression of HOX genes (Mishra et al., 2009) and NF-kB
pathway genes (Robert et al., 2009). Other histone methyltrans-
ferases are also affected by chromosomal translocations, such
as NSD1 (Cerveira et al., 2003) or DOT1L (Okada et al., 2005).
The human DOT1L interacts with AF10, an MLL fusion partner,
causing leukemic transformation in an hDOT1L methyltransfer-
ase activity-dependent manner (Okada et al., 2005), resulting
in the upregulation of several leukemia-relevant genes, such as
HoxA9 (Okada et al., 2005). Interestingly, DOT1L is not recruited
to the promoters that are DNA promoter demethylated after
5-aza-deoxycytidine treatment or genetic deletion of DNAmeth-
yltransferases (Jacinto et al., 2009), suggesting that DNA deme-
thylating interventions alone are not able to restore complete
euchromatic status and full transcriptional reactivation of the
epigenetically silenced tumor-suppressor genes. Regarding
aberrant lysine acetylation, the genes encoding p300, CBP
(CREB binding protein), MOZ, and MORF histone acetyltrans-
ferases are frequently rearranged in recurrent leukemia-associ-
ated chromosomal abnormalities (Yang, 2004). Mistargeting
of such translocations contributes to global alterations in
histone acetylation patterns. In addition, at a specific level, this
leukemia-associated MOZ-CBP fusion protein inhibits p53-
mediated transcription (Rokudai et al., 2009). So far, no roles
for MLL1 and MOZ disruptions have been proposed in solid
tumors. A more detailed list of chromosomal translocations
affecting histone modifiers could be found in Table 1.
Induced-Cell Differentiation Mediated
by Epigenetic Therapy
Unlike genetic alterations, epigenetic changes are potentially
reversible. Reactivation of epigenetically silenced genes has
been possible for years by treatment with DNA demethylation
drugs, such as zebularine and 5-aza-20- deoxycytidine (5-ADC),
or with histone deacetylase (HDACs) inhibitors, including SAHA
(suberoylanilide hydroxamic acid), valproic acid (VPA), and
trichostatin A (TSA). Indeed, some of these drugs have shown
significant antitumor activity, and the US Food and Drug
Table 1. A Representative List of Histone Modifiers Disrupted in Cancers
Gene Name Substrate Specificity Genetic Defect
Gain or Loss
of Function Tumor Type References
PubMed
ID Numbers
Histone acetyltransferases (HATs)
*CBP (KAT3A) H2AK5, H2BK12,
H2BK15, H3K14,
H3K18, H4K5, H4K8
deletion loss ALL; lung Shigeno et al. (2004);
Kishimoto et al. (2005)
15312679;
15701835
CBP (KAT3A) H2AK5, H2BK12,
H2BK15, H3KI14,
H3K18, H4K5, H4K8
mutation loss lung; MSI+ Kishimoto et al. (2005);
Ionov et al. (2004)
15701835;
14732695
*CBP (KAT3A) H2AK5, H2BK12,
H2BK15, H3KI14,
H3K18, H4K5, H4K8
translocation loss AML Panagopoulos et al.
(2001, 2003)
11157802;
12461753
*p300 (KAT3B) H2AK5, H2BK12,
H2BK15
deletion loss cervix; ALL Ohshima et al. (2001);
Shigeno et al. (2004)
11181085;
15312679
p300 (KAT3B) H2AK5, H2BK12,
H2BK15
mutation loss breast; CRC Gayther et al. (2000) 10700188
*p300 (KAT3B) H2AK5, H2BK12,
H2BK15
translocation loss AML Ida et al. (1997);
Chaffanet et al. (2000)
9389684;
10824998
pCAF (KAT2B) H3K9, H3K14,
H3K18; H2B
mutation loss epithelial
cancer
Ozdag et al. (2002);
Zhu et al. (2009)
12402157;
19525977
*MORF (KAT6B) H3K14; H4K16 translocation loss AML Panagopoulos et al. (2001) 11157802
*MOZ (KAT6A) H3K14; H4K16 translocation loss AML Chaffanet et al. (2000);
Panagopoulos et al. (2003)
10824998;
12461753
Histone Methyltransferases (HMTs)
*DOT1L (KMT4) H3K79 translocation loss AML Okada et al. (2005) 15851025
EZH2 (KMT6) H3K27 amplification gain prostate Bracken et al. (2003) 14532106
*EZH2 (KMT6) H3K27 mutation loss lymphoma Morin et al. (2010) 20081860
G9a (KMT1C) H3K9 overexpression gain HCC Kondo et al. (2000) 11050047
*MLL1 (KMT2A) H3K4 translocation loss AML, ALL reviewed in Miremadi
et al. (2007)
17613546
*MLL3 (KMT2C) H3K4 deletion loss leukemia Tan and Chow (2001) 11718452
NSD1 (KMT3B) H3K36, H4K20 CpG hypermethylation loss neuroblastoma,
glioma
Berdasco et al. (2009) 20018718
*NSD1 (KMT3B) H3K36, H4K20 translocation loss AML Jaju et al. (2001) 11493482
NSD3 H3K4, H3K27 amplification gain breast Angrand et al. (2001) 11374904
RIZ1 (KMT8) H3K9 CpG hypermethylation loss breast, liver Du et al. (2001) 11719434
SMYD2 (KMT3C) H3K36 amplification gain ESCS Komatsu et al. (2009) 19423649
SUZ12
(HMT complex)
H3K9, H3K27 translocation loss ESS Li et al. (2007);
Panagopoulos et al. (2008)
18077430,
18722875
Histone deacetylases (HDACs)
HDAC2 Many acetyl residues
(except H4K16)
mutation loss MSI+ Ropero et al. (2006);
Hanigan et al. (2008)
16642021;
18834886
Histone demethylase (HDMTs)
GASC1 (KDM4C) H3K9, H3K36 amplification gain ESCS; lung;
breast
Cloos et al. (2006);
Italiano et al. (2006);
Liu et al. (2009)
16732293;
16737911;
19784073
LSD1 ((KDM1) H3K4, H3K9 amplification gain prostate; bladder;
lung; CRC
Kahl et al. (2006);
Hayami et al. (2010)
17145880;
20333681
UTX (KDM6A) H3K27 mutation loss multiple types van Haaften et al. (2009) 19330029
Enzymes are grouped according to their catalytic activity, including histone acetyltransferases (HATs), histonemethyltransferases (HMTs), histone de-
acetylases (HDACs) and histone demethylases (HDMTs). Hematological malignancies commonly exhibit chromosomal translocations; while solid
tumors are more often affected by different genetic and epigenetic alterations, such as CpG promoter hypermethylation, deletions, point mutations
or gene amplification. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CRC, colorectal carcinoma; ESCS, esophageal squamous
cell carcinoma; ESS, endometrial stromal sarcomas; HCC, hepatocellular carcinoma;MSI+, colorectal carcinomawith microsatellite instability. Genes
affected in leukemia are marked with an asterisk (*).
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ReviewAdministration (FDA) has approved the use of some of them to
treat patients (Esteller, 2005; Kaminskas et al., 2005; Fiskus
et al., 2008; Scuto et al., 2008). However, as we have discussed
above, removing DNA methylation is often insufficient to reacti-
vate gene expression; further study of the interplay with other
chromatin modifications is, therefore, essential. Although this
process is far from trivial, the investment in high-throughput
genetic and biochemical analyses to identify the enzymatic path-
ways involved in the epigenetic machinery is further warranted
by evidence that epigenetic therapy may be applicable to other
disorders as well. As an example, the binding of histone acetyl-
transferase CBP (CREB-binding protein) promotes the activation
of neuronal, astrocytic, and oligodendroglial differentiation
genes (Wang et al., 2010). A recent study demonstrated that
CBP-knockdown mice exhibit a range of cognitive defects
because of impartial cortical precursor differentiation and,
most important, that this phenotype could be reversed by inhibi-
tion of HDACs with TSA (Wang et al., 2010). In addition, in vitro
treatment with chromatin-modifying drugs can alter the potential
of pluripotent and multipotent stem cells to differentiate in vitro
into several lineages. As just one example, the use of DNA deme-
thylation treatment (5-ADC) promotes differentiation of multipo-
tent cells into cardiac myogenic cells (Choi et al., 2004) and
drives the osteogenic differentiation of mesenchymal stem cells
(Zhou et al., 2009).
Bearing in mind this capacity for ‘‘resetting,’’ there are several
examples of how epigenetically deregulated tissue-specific
genes in cancer could restore their differentiated phenotype.
Two different strategies for correcting the aberrant patterns
may be employed: first, by treatment with an epigenetic drug
that directly restores the epigenetic alteration and, second, if
an epigenetic modifier is altered, it is possible to restore the
expression of the gene by genetic techniques. As an example
of the first strategy, an effective use of zebularine in the treatment
of T cell lymphoma has been proposed (Herranz et al., 2006). In
this study, all the animals presented large thymic T lymphomas
but only zebularine-treated mice were able to survive. Interest-
ingly, after treatment, the animals presented a thymus structure
and volume similar to those of normal (non-tumor-prone) mice
(Herranz et al., 2006). As an example of the second strategy,
the in vitro restoration of histonemethyltransferaseNSD1 activity
in neuroblastoma cells that do not express the enzyme was
associated with an increase of glial differentiation (Berdasco
et al., 2009). These results highlight the advantages of epigenetic
therapy in cancer treatment by restoring normal expression of
differentiation-related genes.
Concluding Remarks
It has become increasingly clear that epigenetic mechanisms
play a central role in cellular differentiation and that their dereg-
ulation can contribute to cancer development. In addition to the
epigenetic inactivation of classical tumor-suppressor genes,
there is new evidence that tissue-specific genes may also be
targets for epigenetic deregulation in cancer. Furthermore, aber-
rant profiles of CpG promoter hypermethylation and histone
marks in tumors are not exclusively observed in promoters of
tumor-suppressor genes because promoter hypermethylation
of miRNAs or even the epigenetic machinery itself (NSD1,
RIZ1) could be affected in a tissue-dependent manner. These706 Developmental Cell 19, November 16, 2010 ª2010 Elsevier Inc.findings underline the necessity of evaluating the potential of
epigenetic drugs to erase the pre-established patterns of epige-
netic marks in cancer therapy. Epigenetic factors are highly
dynamic, which means that they are stable, but not static, and
can be modulated by the environment. How dynamic are the
epigenetic profiles of adult differentiated cells? In differentiated
cells, epigenetic marks with short-term flexibility (which could
be removed after a few divisions) coexist with long-term and
more stable marks (maintained for many divisions). According
to Waddington’s epigenetic landscape, it has been accepted
that, during differentiation, there is an increased presence of
stable repressive marks in those genes that are no longer
required, such as pluripotency or nonessential tissue-specific
genes. Indeed, for somemultipotent progenitors, one of the hall-
marks of their plasticity lies in their ability to maintain simulta-
neous expression of diverse competing transcription factors
that would otherwise be tissue-specific and, indeed, drive diver-
gent modes of downstream differentiation (Chang et al., 2008).
Recent investigations have revealed a new complexity to the
concept of cell flexibility and differentiation in animals. Under
certain experimental conditions, differentiated cells can revert
to a less differentiated state in a process known as ‘‘reprogram-
ming.’’ A mature cell can be converted into a pluripotent state by
the in vitro application of a defined set of transcription factors,
creating induced pluripotent stem cells (iPSCs). Generation of
iPSCs has been possible inmany cell types derived from all three
germ layers, implying the operation of ‘‘epigenetic reprogram-
ming.’’ In fact, there is evidence that HDAC inhibitors and G9a
inhibitors are useful in this regard (Huangfu et al., 2008; Shi
et al., 2008). These studies have suggested that the roles of
such factors may be analogous in normal development and in
diseases associated with loss of differentiation, such as cancer.
Consequently, they provide new opportunities for therapy strat-
egies. Further understanding of the epigenetic regulation of
tissue-specific genes along with the development of more
specific epigenetic drugs may hold the key to our ability to
successfully reset the abnormal cancer epigenome.REFERENCES
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